Abbott Laboratories
ABT
$106.86
-$0.03-0.03%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 10.24B | 10.14B | 9.98B | 9.75B | 10.09B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.24B | 10.14B | 9.98B | 9.75B | 10.09B |
| Cost of Revenue | 4.53B | 4.61B | 4.48B | 4.31B | 4.53B |
| Gross Profit | 5.71B | 5.54B | 5.50B | 5.43B | 5.56B |
| SG&A Expenses | 2.58B | 2.60B | 2.62B | 2.62B | 2.74B |
| Depreciation & Amortization | 481.00M | 496.00M | 498.00M | 491.00M | 496.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.18B | 8.37B | 8.32B | 8.07B | 8.34B |
| Operating Income | 2.06B | 1.77B | 1.66B | 1.68B | 1.75B |
| Income Before Tax | 1.80B | 1.67B | 1.64B | 1.56B | 1.32B |
| Income Tax Expenses | 201.00M | 235.00M | 261.00M | 244.00M | 287.00M |
| Earnings from Continuing Operations | 1.59B | 1.44B | 1.38B | 1.32B | 1.03B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.59B | 1.44B | 1.38B | 1.32B | 1.03B |
| EBIT | 2.06B | 1.77B | 1.66B | 1.68B | 1.75B |
| EBITDA | 2.87B | 2.59B | 2.46B | 2.48B | 2.56B |
| EPS Basic | 0.91 | 0.82 | 0.79 | 0.75 | 0.59 |
| Normalized Basic EPS | 0.69 | 0.60 | 0.59 | 0.58 | 0.61 |
| EPS Diluted | 0.91 | 0.82 | 0.78 | 0.75 | 0.59 |
| Normalized Diluted EPS | 0.69 | 0.60 | 0.58 | 0.57 | 0.61 |
| Average Basic Shares Outstanding | 1.75B | 1.74B | 1.74B | 1.74B | 1.75B |
| Average Diluted Shares Outstanding | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B |
| Dividend Per Share | 0.55 | 0.51 | 0.51 | 0.51 | 0.51 |
| Payout Ratio | 55.71% | 61.84% | 64.73% | 67.53% | 79.67% |
